Pterosin A
Based on 1 Customer Validation
Pterosin A ((2S)-Pterosin A) is a sesquiterpene compound. Pterosin A is an orally active AMPK activator with anti-diabetic effect. Pterosin A can promote glucose uptake, increase serum insulin, and improve hyperglycemia and glucose intolerance. Pterosin A can prevent insulin-secreting cells death and reduce ROS production. Pterosin A can be used for the research of metabolic disease, such as diabetes.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 94.07%
- CAS No.: 35910-16-8
- 화학식: C15H20O3
- 분자량:248.32
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
All AMPK Isoforms
More
Biological Activity
제품 설명
IC50 & Target
[1]|
GLUT4 |
p-GSK-3 |
In Vitro
Pterosin A (50 μg/mL, 0.5-4 h) enhances glucose uptake and AMPK phosphorylation in muscle cells[1].
Pterosin A (50-150 μg/mL, 0.5-4 h) inhibits PEPCK expression, triggers the phosphorylations of AMPK, ACC, and GSK-3, decreases glycogen synthase phosphorylation, and increases the intracellular glycogen level in liver cells[1].
Pterosin A (10-100 μM, 18 h) inhibits H2O2-induced ROS production in RINm5f β-cells[2].
Pterosin A (10-100 μM, 24 h) reduces lipotoxicity-induced cell death in RINm5f β-cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Liver cells
-
Concentration:50 and 150 μg/mL
-
Incubation Time:0.5, 1, 2 and 4 h
-
Result:Increased p-AMPK and P-ACC and p-GSK3-α/β levels.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Streptozotocin (HY-13753), high-fat diet-fed and db/db diabetic mice models[1]
-
Dosage:10, 30 and 100 mg/kg
-
Administration:Orally administration, daily for 4 weeks
-
Result:Reversed the increased serum insulin and insulin resistance in dexamethasone-IR mice.
Reversed the reduced muscle GLUT-4 translocation and the increased liver phosphoenolpyruvate carboxyl kinase (PEPCK) expression.
Reversed the decreased phosphorylations of AMP-activated protein kinase (AMPK) and Akt in muscles.
Reversed increased p38 phosphorylation in livers.
Chemical Information
-
CAS No. 35910-16-8
-
Appearance Solid
-
분자량 248.32
-
화학식 C15H20O3
-
Color White to off-white
-
SMILES
O=C1C(C(C[C@](C)1CO)=CC(C)=C2CCO)=C2C
-
Synonyms
(2S)-Pterosin A
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Protocol
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
순도&문서
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hsu FL, et al. Antidiabetic effects of pterosin A, a small-molecular-weight natural product, on diabetic mouse models. Diabetes. 2013 Feb;62(2):628-38. [Content Brief]
[2]. Chen CY, et al. Chemical constituents analysis and antidiabetic activity validation of four fern species from Taiwan. Int J Mol Sci. 2015 Jan 22;16(2):2497-516. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)